SCHEMBL10300893

SCHEMBL10300893

Cc1ccc(-c2ccc3c(-c4ccccc4)c4ccccc4c(-c4ccccc4)c3c2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CYP2A6 P11509 1/20 0.47
CCR1 P32246 1/20 0.44
CCR5 P51681 1/20 0.44
CCR8 P51685 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
P2RX7 Q99572 1/20 0.38
PSMB5 P28074 1/20 0.38
ACHE P22303 1/20 0.38
PIM1 P11309 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15161016 0.94 CYP3A4 (0.45) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL15977627 0.94 CYP3A4 (0.45) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL18174644 0.94 CYP3A4 (0.45) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL18174600 0.92 CYP3A4 (0.43) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL18174581 0.92 CYP3A4 (0.43) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL10032730 0.88 CYP3A4 (0.45) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL18174561 0.87 CCR1 (0.54) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL10032691 0.87 CYP3A4 (0.44) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL15977410 0.86 CTRC (0.42) CYP3A4CYP2A6CCR1CCR5CCR8
SCHEMBL10300887 0.86 HSD17B1 (0.47) CYP11B1CYP11B2PSMB5SMN1; SMN2HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2022-12-29 US disclosed
US-8217570-B2 Anthracene derivative and organic electroluminescent element using the same IDEMITSU KOSAN CO., LTD. (JP) 2012-07-10 US disclosed
US-8217570-B2 Anthracene derivative and organic electroluminescent element using the same IDEMITSU KOSAN CO., LTD. (JP) 2012-07-10 US disclosed
US-20080111473-A1 Anthracene Derivative and Organic Electroluminescent Element Using the Same IDEMITSU KOSAN CO., LTD. (JP) 2008-05-15 US disclosed
US-20080111473-A1 Anthracene Derivative and Organic Electroluminescent Element Using the Same IDEMITSU KOSAN CO., LTD. (JP) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS PIEZO1, TMEM109, SLC39A14 CYP3A4 1266/4885CYP2A6 3184/4885CCR1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.